You are here

Academic, AstraZeneca Scientists Join to Study Key Risk Factor for Alzheimer’s Disease

Under the terms of the new collaboration, called the A5 Alliance, AstraZeneca will fund the academic research, and members of the company’s Neuroscience Innovative Medicines unit will manage the program and contribute scientific expertise. The academic members of the alliance will contribute their disease-area knowledge and expertise, as well as lead specific aspects of the research program in their laboratories.

Dr. Steven Paul, principal academic collaborator, said: “We are convinced that ApoE represents a major piece of the Alzheimer's disease puzzle and that each member of the A5 Alliance brings a critical piece of that puzzle to the table."

The ApoE genotype is considered second only to age as a risk factor for the development of Alzheimer's disease. Drug discovery efforts involving the genotype have been hindered, however, by the challenging biology and by a lack of in vivo models.

Source: Weill-Cornell news release

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function